This CX Programme is subject to change.


Search for words

Peripheral Proximal Arterial Ischaemia Challenges - Tuesday, 16th April
Venue:   Upper Main Auditorium
Time: 08:00 - 18:00
Peripheral arterial disease issues
Chairing:   Cliff Shearman, Southampton, United Kingdom
Moderator:   Barry Katzen, Miami, United States
Time: 08:00 - 08:08
Treatment of claudication is aimed to increase walking distance, improve quality of life and prevent cardiovascular events by reducing risk factors
Speaker:   Sanne Klaphake, Rotterdam, Netherlands
Time: 08:08 - 08:16
Female gender is a risk factor for poor outcomes after revascularisation for peripheral arterial disease
Speaker:   Ruth Benson, Birmingham, United Kingdom
Time: 08:16 - 08:24
Audience participation and discussion
Time: 08:24 - 08:32
Office-based lower extremity arterial interventions are feasible, safe, cost-effective and patients love it
Speaker:   Enrico Ascher, Brooklyn, United States
Time: 08:32 - 08:40
Ambulatory treatment of arterial disease - European perspective
Speaker:   Yann Gouëffic, Nantes, France
Time: 08:40 - 08:48
Audience participation, discussion and polling
Time: 08:48 - 08:56
Appropriate follow-up of patients after endovascular procedures
Speaker:   Marianne Brodmann, Graz, Austria
Time: 08:56 - 09:04
Open or endovascular repair for popliteal artery aneurysms - A case-control study
Speaker:   Martin Björck, Uppsala, Sweden
Time: 09:04 - 09:12
Audience participation and discussion
 
Imaging
Chairing:   Robert Morgan, President CIRSE, London, United Kingdom
Moderator:   Andrew Holden, Auckland, New Zealand
Time: 09:12 - 09:20
Assessment of the perfusion with indocyanine green fluorescence imaging (ICG-FI) before and after revascularisation tells the success of revascularisation
Speaker:   Maarit Venermo, Helsinki, Finland
Time: 09:20 - 09:28
Tips and tricks to optimise CO2 angiography (including work-up with no-contrast MR angiography)
Speaker:   Jos van den Berg, Lugano, Switzerland
Time: 09:28 - 09:36
Audience participation and discussion
Time: 09:36 - 09:44
IVUS sizing improves outcomes of DCB therapy in the femoropopliteal segment
Speaker:   Phillip Puckridge, Marion, Australia
Time: 09:44 - 09:52
Contrast-enhanced tomographic 3D ultrasound imaging of peripheral arterial disease and potential autologous bypass grafts
Speaker:   Steven Rogers, Manchester, United Kingdom
Time: 09:52 - 10:00
Audience participation, discussion and polling
 
Coffee and visit to hands-on workshops
Time: 10:00 - 10:30
Coffee Symposium: The paclitaxel safety controversy - from patient-level data to big data: What the newest clinical evidence is telling us
Time: 10:03 - 10:28
Chairing:   Peter Schneider, Honolulu, United States
Moderator:   Giovanni Torsello, Münster, Germany
Time: 10:03 - 10:09
Patient-level data from the IN.PACT Clinical Programme: Is paclitaxel safe for the treatment of PAD?
Speaker:   Peter Schneider, Honolulu, United States
Time: 10:09 - 10:15
Two-year outcomes from four pooled multicentre RCTs: Safety after treatment with paclitaxel-coated balloons
Speaker:   Thomas Albrecht, Berlin, Germany
Time: 10:15 - 10:21
Big data: What does it tell us about survival following PAD revascularisation using drug technologies?
Speaker:   Eric Secemsky, Boston, United States
Time: 10:21 - 10:28
Audience participation and discussion
 
Paclitaxel debate
Chairing:   Gunnar Tepe, Rosenheim, Germany
Moderator:   Thomas Zeller, Bad Krozingen, Germany
Time: 10:30 - 10:40
CX Debate: DCB alone is enough for the popliteal segment

For the motion
Time: 10:30 - 10:35
Marc Bosiers, Dendermonde, Belgium

Against the motion
Time: 10:35 - 10:40
Theodosios Bisdas, Athens, Greece

Time: 10:40 - 10:50
Audience participation, discussion and polling
 
Paclitaxel: The last word
Chairing:   Roger Greenhalgh, London, United Kingdom
Moderators:   Andrew Holden, Auckland, New Zealand
Gunnar Tepe, Rosenheim, Germany
Thomas Zeller, Bad Krozingen, Germany
Review of the findings of the VIVA Forum
Time: 10:50 - 11:00
Paclitaxel summary of VIVA
Speaker:   Gary Ansel, Columbus, United States
Time: 11:00 - 11:10
Audience participation, discussion and polling
 
The potential problem
Time: 11:10 - 11:20
My choices of DCB and DES data to combine in meta-analysis and my conclusions
Speaker:   Konstantinos Katsanos, Patras, Greece
Time: 11:20 - 11:27
BASIL 3 - withdrawal of paclitaxel use
Speaker:   Jonathan Michaels, Sheffield, United Kingdom
Time: 11:27 - 11:34
SWEDEPAD trials - withdrawal of paclitaxel use
Speaker:   Marten Falkenberg, Gothenburg, Sweden
Time: 11:34 - 11:50
Audience participation, discussion and polling
 
Scrutiny of paclitaxel and the way forward
Time: 11:50 - 12:00
Statistical review of methodology and legitimacy of results
Speaker:   Sue Duval, Minneapolis, United States
Time: 12:00 - 12:10
Statistical issues
Speaker:   Jon Deeks, Birmingham, United Kingdom
Time: 12:10 - 12:30
Audience participation, discussion and polling
 
Lunch and visit to hands-on workshops
Time: 12:30 - 13:30
Lunch Symposium: Optimising DCB results for long-term success
Time: 12:33 - 12:58
Chairing:   Michael Lichtenberg, Arnsberg, Germany
Moderator:   Gary Ansel, Columbus, United States
Time: 12:33 - 12:41
Long-term safety and efficacy update of a low-dose DCB
Speaker:   Gary Ansel, Columbus, United States
Time: 12:41 - 12:49
The benefits of IVUS in DCB treatment of the femoropopliteal segment
Speaker:   Phillip Puckridge, Marion, Australia
Time: 12:49 - 12:58
The value of effective vessel preparation before DCB use
Speaker:   Theodosios Bisdas, Athens, Greece
 
Review of paclitaxel usage: The way forward
Chairing:   Roger Greenhalgh, London, United Kingdom
Moderators:   Andrew Holden, Auckland, New Zealand
Gunnar Tepe, Rosenheim, Germany
Thomas Zeller, Bad Krozingen, Germany
Time: 13:30 - 13:38
What the FDA are looking for in data requested
Speaker:   Misti Malone, Silver Spring, United States
Time: 13:38 - 13:46
What MHRA are looking for
Speaker:   Hazel Randall, London, United Kingdom
Time: 13:46 - 13:56
Audience participation, discussion and polling
Time: 13:56 - 14:04
Paclitaxel early advances to limit restenosis
Speaker:   Ulrich Speck, Berlin, Germany
Time: 14:04 - 14:12
Paclitaxel: Why a chemotherapeutic was chosen to prevent restenosis - rationale and early experience
Speaker:   Lindsay Machan, Vancouver, Canada
Time: 14:12 - 14:20
Paclitaxel as primary therapy in oncology - benefits, doses, levels compared
Speaker:   Erica Mayer, Boston, United States
Time: 14:20 - 14:35
Audience participation, discussion and polling
Time: 14:35 - 14:43
Lessons learned from the experience in the coronary arteries - sirolimus, paclitaxel and everolimus
Speaker:   Bruno Scheller, Homburg, Germany
Time: 14:43 - 14:51
Potential toxicity of paclitaxel in vascular interventions and pharmacokinetic aspects
Speaker:   Aloke Finn, Gaithersburg, United States
Time: 14:51 - 14:59
Paclitaxel effects on the human artery wall and insights from pathology
Speaker:   Elena Ladich, Hollywood, FL, United States
Time: 14:59 - 15:30
Audience participation, discussion and polling
 
Tea and visit to hands-on workshops
Time: 15:30 - 16:00
Tea Symposium: Aortoiliac obstructive disease: Endoluminal solutions
Time: 15:33 - 15:58
Chairing:   Michele Antonello, Padua, Italy
Time: 15:33 - 15:39
Complexity of iliac occlusive disease, current treatment algorithm and treatment gaps
Speaker:   Michele Antonello, Padua, Italy
Time: 15:39 - 15:45
Challenging bilateral iliac case treated with a new balloon-expandable endoprosthesis
Speaker:   Hany Zayed, London, United Kingdom
Time: 15:45 - 15:51
Complex iliac occlusive disease: Treatment with covered stent grafts
Speaker:   Gianmarco de Donato, Siena, Italy
Time: 15:51 - 15:58
Audience participation and discussion
 
Edited case
Chairing:   Michele Antonello, Padua, Italy
Time: 16:00 - 16:30
Edited case: Treating iliac occlusive disease with a covered endoprosthesis
Case presenter:   Andrew Holden, Auckland, New Zealand
 
Interventional techniques
Chairing:   Gunnar Tepe, Rosenheim, Germany
Moderator:   Robert Hinchliffe, Bristol, United Kingdom
Time: 16:30 - 16:37
Advantages and results of treating SFA-popliteal occlusive lesions with a dual component stent: From the Austrian Registry
Speaker:   Martin Werner, Vienna, Austria
Time: 16:37 - 16:44
How to treat in-stent-restenosis in the femoropopliteal tract - what the literature tells us
Speaker:   Marc Bosiers, Dendermonde, Belgium
Time: 16:44 - 16:51
The case for spot stenting - similarities and differences between techniques
Speaker:   Thomas Zeller, Bad Krozingen, Germany
 
Edited case
Time: 16:51 - 17:21
Edited case: Focal dissection repair after femoropopliteal angioplasty
Case presenter:   Michael Lichtenberg, Arnsberg, Germany
Time: 17:21 - 17:28
Femoropopliteal bypasses with heparin-bonded PTFE are a durable treatment for long SFA-popliteal occlusions: When they are the best treatment and why
Speaker:   Walter Dorigo, Florence, Italy
Time: 17:28 - 17:40
Audience participation and discussion
 
Open bypass
Time: 17:40 - 17:50
CX Debate: In the absence of suitable venous graft material prosthetic bypass is the answer

For the motion
Time: 17:40 - 17:45
Clement Darling III, Albany, United States

Against the motion
Time: 17:45 - 17:50
Andrew Holden, Auckland, New Zealand

Time: 17:50 - 18:00
Audience participation, discussion and polling